Page last updated: 2024-09-04

abiraterone and Cardiotoxicity

abiraterone has been researched along with Cardiotoxicity in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (33.33)	24.3611
2020's	2 (66.67)	2.80

Authors

Authors	Studies
Bretagne, M; Dureau, P; Funck-Brentano, C; Lebrun-Vignes, B; Malouf, GG; Moslehi, JJ; Pariente, A; Potey, C; Roden, DM; Salem, JE; Shaffer, CM	1
Addison, D; Baliga, R; Calaway, AC; Campbell, CM; Challa, AA; Cullen, J; Desai, N; Deswal, A; Garcia, J; Guha, A; Kutty, S; Vallakati, A; Weintraub, NL	1

Reviews

2 review(s) available for abiraterone and Cardiotoxicity

Article	Year
Cardiovascular Toxicities of Androgen Deprivation Therapy. Current treatment options in oncology, 2021, 04-17, Volume: 22, Issue:6 Topics: Androstenes; Antineoplastic Agents, Hormonal; Cardiotoxicity; Cardiovascular Diseases; COVID-19; Disease Susceptibility; Gonadotropin-Releasing Hormone; Health Status Disparities; Humans; Male; Prostatic Neoplasms; SARS-CoV-2	2021
Differential Side Effects Profile in mCRPC Patients Treated With Abiraterone or Enzalutamide: A Meta-Analysis of Randomized Controlled Trials. Clinical advances in hematology & oncology : H&O, 2016, Volume: 14, Issue:4 Suppl 5 Topics: Androstenes; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cardiotoxicity; Clinical Trials, Phase III as Topic; Humans; Male; Nitriles; Odds Ratio; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Randomized Controlled Trials as Topic	2016

Article

Year

Cardiovascular Toxicities of Androgen Deprivation Therapy.

Current treatment options in oncology, 2021, 04-17, Volume: 22, Issue:6

Topics: Androstenes; Antineoplastic Agents, Hormonal; Cardiotoxicity; Cardiovascular Diseases; COVID-19; Disease Susceptibility; Gonadotropin-Releasing Hormone; Health Status Disparities; Humans; Male; Prostatic Neoplasms; SARS-CoV-2

2021

Differential Side Effects Profile in mCRPC Patients Treated With Abiraterone or Enzalutamide: A Meta-Analysis of Randomized Controlled Trials.

Clinical advances in hematology & oncology : H&O, 2016, Volume: 14, Issue:4 Suppl 5

Topics: Androstenes; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cardiotoxicity; Clinical Trials, Phase III as Topic; Humans; Male; Nitriles; Odds Ratio; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Randomized Controlled Trials as Topic

2016

Other Studies

1 other study(ies) available for abiraterone and Cardiotoxicity

Article	Year
Heart failure and atrial tachyarrhythmia on abiraterone: A pharmacovigilance study. Archives of cardiovascular diseases, 2020, Volume: 113, Issue:1 Topics: Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Androgen Antagonists; Androstenes; Antineoplastic Agents, Hormonal; Benzamides; Cardiotoxicity; Databases, Factual; Heart Failure; Humans; Male; Middle Aged; Nitriles; Pharmacovigilance; Phenylthiohydantoin; Prostatic Neoplasms; Retrospective Studies; Risk Assessment; Risk Factors; Tachycardia, Supraventricular; Time Factors	2020

Article

Year

Heart failure and atrial tachyarrhythmia on abiraterone: A pharmacovigilance study.

Archives of cardiovascular diseases, 2020, Volume: 113, Issue:1

Topics: Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Androgen Antagonists; Androstenes; Antineoplastic Agents, Hormonal; Benzamides; Cardiotoxicity; Databases, Factual; Heart Failure; Humans; Male; Middle Aged; Nitriles; Pharmacovigilance; Phenylthiohydantoin; Prostatic Neoplasms; Retrospective Studies; Risk Assessment; Risk Factors; Tachycardia, Supraventricular; Time Factors

2020